AptarGroup, Inc.

AptarGroup, Inc. (ATR) Stock Analysis

$124.510

+0.249 (+0.20%)At close

Loading chart…
High
125.985
Open
125.080
VWAP
124.89
Volume
550.21K
Mkt Cap
9.53B
Low
124.175
Amount
68.72M
EV/EBITDA, TTM
11.10

AptarGroup, Inc. is engaged in the design and manufacturing of drug and consumer product dosing, dispensing, and protection technologies. The Company serves diversified end markets including pharmaceutical, fragrance, facial skincare, color cosmetics, food, beverage, personal care, and home care. It also manufactures and sells elastomeric primary packaging components. It operates through three segments, which include the Pharma segment, Beauty segment, and Closures segment. The Pharma segment is a supplier of nasal drug delivery spray pumps and metered dose inhaler valves (MDIs) to the pharmaceutical and health care markets worldwide. The Beauty segment sells pumps, airless systems and valves to the fragrance, color cosmetics, facial skincare, personal care, and home care markets. The Closures segment includes dispensing and non-dispensing solutions that enable product delivery without removal of the cap and are used across multiple consumer end markets.

www.aptar.com

AI analysis of AptarGroup, Inc. (ATR)

Buy

Aptargroup Inc is a good buy right now due to its current price of $124.51 being below the analyst price target range, with a forward P/E of 19.76 indicating attractive valuation. The RSI is at 71.48, suggesting it may be overbought, but the recent positive news about securing CE Mark for its device could drive future growth. The main risk is the recent decline below the 200-day moving average, which could indicate a bearish trend.

Analyst Ratings (9)

+16.72% upside
Hold
2 Buy
6 Hold
1 Sell
Current: 124.51
Low
133.00
Average
145.33
High
156.00

UBS

2026-10-09

Price Target

$135

Neutral

BofA

2026-10-06

Price Target

$154

Buy

BofA

2026-07-31

Price Target

$172

Buy

Raymond James

2026-07-15

Price Target

$160

Outperform

BofA

2026-07-14

Price Target

$173

Buy

Valuation Metrics

The current forward P/E ratio for AptarGroup, Inc. (ATR) is 19.76, compared to its 5-year average forward P/E of 25.38.

Forward P/E

Undervalued
5Y Average P/E
25.38
Current P/E
19.76
Overvalued
28.98
Undervalued
21.78

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
12.77
Current EV/EBITDA
11.10
Overvalued
13.82
Undervalued
11.73

Forward P/S

Undervalued
5Y Average P/S
2.31
Current P/S
1.91
Overvalued
2.62
Undervalued
2.00

Alphio AI Price Scenarios for ATR

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%ATR

$180.85

Scenario price

B

Base

Base · 50%ATR

$171.26

Scenario price

B

Bear

Bear · 25%ATR

$163.57

Scenario price

Whales holding ATR

H

Howard Capital Management, Inc.

+ HoldingATR

+12.71%

3M Return

W

Williams Jones Wealth Management, LLC

+ HoldingATR

+3.59%

3M Return

H

Hemenway Trust Company LLC

+ HoldingATR

+3.30%

3M Return

R

Reynders, McVeigh Capital Management, LLC

+ HoldingATR

+0.68%

3M Return

S

Schwartz Investment Counsel, Inc.

+ HoldingATR

+0.07%

3M Return

E

Edgestream Partners, L.P.

+ HoldingATR

-2.64%

3M Return

Events Timeline

2026-09-14 (ET)

17:30:00

AptarGroup Signs Research Collaboration Agreement with MGH

2026-07-30 (ET)

17:30:00

Aptar Reports Q2 Revenue of $1.03B, Beating Expectations

17:30:00

Aptar Optimistic About Q3 Outlook

2026-04-30 (ET)

17:10:00

Aptar CEO Predicts Growth Across Segments in Q2

17:10:00

Aptar Q1 Revenue $982.9M Beats Expectations

News

ATR FAQ — answered by Alphio AI

AptarGroup, Inc. is engaged in the design and manufacturing of drug and consumer product dosing, dispensing, and protection technologies. The Company serves diversified end markets including pharmaceutical, fragrance, facial skincare, color cosmetics, food, beverage, personal care, and home care. It also manufactures and sells elastomeric primary packaging components. It operates through three segments, which include the Pharma segment, Beauty segment, and Closures segment. The Pharma segment is a supplier of nasal drug delivery spray pumps and metered dose inhaler valves (MDIs) to the pharmaceutical and health care markets worldwide. The Beauty segment sells pumps, airless systems and valves to the fragrance, color cosmetics, facial skincare, personal care, and home care markets. The Closures segment includes dispensing and non-dispensing solutions that enable product delivery without removal of the cap and are used across multiple consumer end markets. It operates in the Basic Materials sector (PLASTICS PRODUCTS, NEC industry).

Aptargroup Inc is a good buy right now due to its current price of $124.51 being below the analyst price target range, with a forward P/E of 19.76 indicating attractive valuation. The RSI is at 71.48, suggesting it may be overbought, but the recent positive news about securing CE Mark for its device could drive future growth. The main risk is the recent decline below the 200-day moving average, which could indicate a bearish trend.

9 analysts cover ATR: 2 rate it Buy, 6 Hold and 1 Sell. The average price target is 145.33.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading